雷公藤多苷对糖尿病肾病大鼠肾性炎性损伤的保护作用
|
摘要
目的观察分析雷公藤多苷改善糖尿病肾病大鼠肾性炎性损伤的保护效果。方法选择75只雄性SD大鼠作为研究对象,包含10只大鼠为对照组,另外65只大鼠为模型组,通过腹腔注射链脲佐菌素建立糖尿病肾病大鼠模型,共64只大鼠成功,并采用随机数字抽取表法将成功的大鼠分为模型组、雷公藤多苷组和罗格列酮组,雷公藤多苷组又分为9mg/kg、18mg/kg。观察分析给药后不同组大鼠的尿素氮、血肌酐、24h尿蛋白量、血清中IL-1β水平,血清IL-17水平、IFN-y水平。结果模型组与对照组相比,其尿素氮、血肌酐、24h尿蛋白量含量、血清IL-1β、血清IL-17、IFN-y水平含量显著升高,数据比较差异具有统计学意义(P<0.05);9mg/kg雷公藤多苷组、18mg/kg雷公藤多苷组和罗格列酮组与模型组相比,尿素氮、血肌酐、24h尿蛋白量含量显著降低,数据比较差异具有统计学意义(P<0.05)。18mg/kg雷公藤多苷组和罗格列酮组与模型组相比,血清IL-1β、血清IL-17、IFN-y水平显著降低,数据比较差异具有统计学意义(P<0.05)。结论雷公藤多苷改善糖尿病肾病大鼠肾性炎性损伤效果显著,能够明显降低血清和肾脏炎性因子水平,实现对肾脏的保护,具有较高的研究价值。
Objective To observe the protective effect of tripterygium glycosides on renal inflammatory injury in diabetic nephropathy rats.Methods 75 male SD rats were used as research materials,including 10 rats in control group and 65 rats in the model group by intraperitoneal injection of streptozotocin diabetic nephropathy rats,and 64 rats were successful. According to the random number table method,the success of extraction the rats were randomly divided into model group,tripterygium glycosides group and rosiglitazone group,and tripterygium glycosides group was divided into 9mg/kg and 18mg/kg. The different groups of rats after treatment on urea nitrogen,serum creatinine,24 h urine protein,serum IL-1β levels,serum IL-17 levels,IFN-y levels were observed and analyzed. Results Comparing with the control group,the blood urea nitrogen,creatinine and 24 h urinary protein content,serum IL-1β,serum IL-17 and beta IFN-y levels of the model group increased significantly,and there was statistically significant difference( P < 0. 05). The 9mg/kg tripterygium glycosides group,18mg/kg group tripterygium glycosides group and rosiglitazone group was compared with the model group,the urea nitrogen,serum creatinine and 24 h urine protein content decreased significantly,and there was statistically significant difference( P < 0. 05). Comparing with the model group,serum IL-1β,serum IL-17 and IFN-y levels of the tripterygium glycosides group and rosiglitazone group were significantly lower than those of the model group( P < 0. 05). The difference was statistically significant( P < 0. 05). Conclusion The tripterygium glycosides can improve renal inflammatory injury in diabetic nephropathy rats,can significantly reduce the level of inflammatory cytokines in serum and kidney,and has a high research value.
Objective To observe the protective effect of tripterygium glycosides on renal inflammatory injury in diabetic nephropathy rats.Methods 75 male SD rats were used as research materials,including 10 rats in control group and 65 rats in the model group by intraperitoneal injection of streptozotocin diabetic nephropathy rats,and 64 rats were successful. According to the random number table method,the success of extraction the rats were randomly divided into model group,tripterygium glycosides group and rosiglitazone group,and tripterygium glycosides group was divided into 9mg/kg and 18mg/kg. The different groups of rats after treatment on urea nitrogen,serum creatinine,24 h urine protein,serum IL-1β levels,serum IL-17 levels,IFN-y levels were observed and analyzed. Results Comparing with the control group,the blood urea nitrogen,creatinine and 24 h urinary protein content,serum IL-1β,serum IL-17 and beta IFN-y levels of the model group increased significantly,and there was statistically significant difference( P < 0. 05). The 9mg/kg tripterygium glycosides group,18mg/kg group tripterygium glycosides group and rosiglitazone group was compared with the model group,the urea nitrogen,serum creatinine and 24 h urine protein content decreased significantly,and there was statistically significant difference( P < 0. 05). Comparing with the model group,serum IL-1β,serum IL-17 and IFN-y levels of the tripterygium glycosides group and rosiglitazone group were significantly lower than those of the model group( P < 0. 05). The difference was statistically significant( P < 0. 05). Conclusion The tripterygium glycosides can improve renal inflammatory injury in diabetic nephropathy rats,can significantly reduce the level of inflammatory cytokines in serum and kidney,and has a high research value.
引文
[1]刘战国.益肾清利活血方联合雷公藤多苷片治疗慢性肾小球肾炎的疗效分析[J].光明中医,2013,28(7):1385-1386.
[2]尹保奇,宋鹏娟.中西医结合治疗糖尿病肾病疗效观察[J].光明中医,2013,28(9):1908-1909.
[3]刘国玲,沈永杰,尤丽菊,等.雷公藤多苷降低糖尿病肾病大鼠炎性细胞因子的表达[J].细胞与分子免疫学杂志,2014,30(7):721-724.
[4]张丽敏,李鸿燕,高燕,等.雷公藤多苷对糖尿病肾病大鼠肾损伤的保护作用及可能机制[J].中国老年学,2016,36(14):3389-3391.
[5]黄燕如,万毅刚,孙伟,等.雷公藤多苷调节肾组织p38MAPK信号通路改善糖尿病肾病肾小球炎症性损伤的作用和机制[J].中国中药杂志,2014,39(21):4102-4109.
[6]王军,程晓霞,朱晓玲,等.益气补肾方联合雷公藤多苷对糖尿病肾病大鼠肾脏VEGF表达及血清炎症因子分泌的影响[J].中国现代应用药学,2016,33(6):711-716.
[7]张巍,任小军,赵晨光,等.雷公藤多苷对糖尿病肾病大鼠肾组织Smad2/3蛋白与Ⅳ型胶原的影响[J].中国中西医结合肾病杂志,2014,15(6):487-490.
[8]宋纯东,侯小静,薛黎明,等.雷公藤多苷片对糖尿病肾病大鼠肾组织WT1的影响[J].中华中医药杂志,2015,30(12):4472-4474.
[9]Li C,Sun W,Du H,et al.miRNAs Expression and Role of Dicer on Podocyte Injury in PAN Nephrosis Rats[J].Chinese Medicine,2015,6(1):13-19.
[10]Veglia E,Grange C,Pini A,et al.Histamine receptor expression in human renal tubules:a comparative pharmacological evaluation[J].Inflammation Research,2015,64(3):261-270.
[2]尹保奇,宋鹏娟.中西医结合治疗糖尿病肾病疗效观察[J].光明中医,2013,28(9):1908-1909.
[3]刘国玲,沈永杰,尤丽菊,等.雷公藤多苷降低糖尿病肾病大鼠炎性细胞因子的表达[J].细胞与分子免疫学杂志,2014,30(7):721-724.
[4]张丽敏,李鸿燕,高燕,等.雷公藤多苷对糖尿病肾病大鼠肾损伤的保护作用及可能机制[J].中国老年学,2016,36(14):3389-3391.
[5]黄燕如,万毅刚,孙伟,等.雷公藤多苷调节肾组织p38MAPK信号通路改善糖尿病肾病肾小球炎症性损伤的作用和机制[J].中国中药杂志,2014,39(21):4102-4109.
[6]王军,程晓霞,朱晓玲,等.益气补肾方联合雷公藤多苷对糖尿病肾病大鼠肾脏VEGF表达及血清炎症因子分泌的影响[J].中国现代应用药学,2016,33(6):711-716.
[7]张巍,任小军,赵晨光,等.雷公藤多苷对糖尿病肾病大鼠肾组织Smad2/3蛋白与Ⅳ型胶原的影响[J].中国中西医结合肾病杂志,2014,15(6):487-490.
[8]宋纯东,侯小静,薛黎明,等.雷公藤多苷片对糖尿病肾病大鼠肾组织WT1的影响[J].中华中医药杂志,2015,30(12):4472-4474.
[9]Li C,Sun W,Du H,et al.miRNAs Expression and Role of Dicer on Podocyte Injury in PAN Nephrosis Rats[J].Chinese Medicine,2015,6(1):13-19.
[10]Veglia E,Grange C,Pini A,et al.Histamine receptor expression in human renal tubules:a comparative pharmacological evaluation[J].Inflammation Research,2015,64(3):261-270.